Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Decitabine injection	TA270 - Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal)
Deep Blue®		Lifting agent for use during complex EMR/ESD procedures
Deferasirox (Exjade)
Deferiprone tablets (Ferriprox)		NHSE commissioned.
Denosumab injection (Xgeva®)	TA265 - Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours
Dermabond®
Desferrioxamine injection		NHSE commissioned - NICE NG8.
Desflurane
Desmopressin injection		Hospital use only
Dexamethasone (Ozurdex®) 700mcg intravitreal implant	TA229 - Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.